Bayer(US:BAYRY) 生物世界·2026-03-11 04:13Core Insights - Bayer Co.Lab has welcomed two biotech startups, Arbele and Mingcheng Bio, to its global co-creation platform, aiming to accelerate innovative drug development and provide breakthrough treatments for patients [1][3] - The inclusion of these companies highlights China's significant potential as a source of innovation in the biopharmaceutical sector, with Bayer Co.Lab having attracted a total of 12 local startups within just over a year [1][6] Group 1: Arbele - Arbele is focused on developing precision therapies for solid tumors, particularly targeting the CDH17 marker, and has advanced its core project ARB202 into the dose-expansion phase after completing Phase I studies [4] - The company aims to leverage Bayer's global resources to expedite its research and development processes, addressing urgent medical needs in cancer treatment [3][4] Group 2: Mingcheng Bio - Mingcheng Bio specializes in GPCR-related technology services and has developed an integrated early drug discovery platform that addresses challenges in GPCR drug development [5] - The company has established a library of over 170 active GPCR proteins and has completed numerous cryo-electron microscopy structural analyses, enhancing its capabilities in antibody discovery and functional screening [5] Group 3: Bayer Co.Lab Overview - Bayer Co.Lab officially launched in China in September 2024, and with the addition of Arbele and Mingcheng Bio, it has formed a diverse biopharmaceutical innovation cluster that includes small molecules, nucleic acid drugs, and AI drug discovery [6] - The platform aims to foster open collaboration within the biotechnology ecosystem, facilitating the transformation of innovative results into impactful healthcare solutions [6]